New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology "The new products we have planned for 2024 will take 10x to ...
PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
PLEASANTON, Calif., Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global ...
Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/ ...
• Troy Randall – Med – Clinical Immunology and Rheumatology - The epigenetic modifier Kmt2a regulates humoral responses to influenza by orchestrating B cell function in the pre-inducible ...
Insights generated from this program are intended to support future clinical diagnostic development. CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this ...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. 10x Genomics is collaborating with PharosAI and leading UK institutions to build ...
PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results